此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda (FACEIT-FU)

2026年11月16日 更新者:Jennifer Keiser

Change in Soil-transmitted Helminth Infection Intensity Following Mass Drug Administration With Ivermectin Plus Albendazole or Albendazole Alone in Ugandan Schoolchildren: a Follow-up Study to Assess Potential Drug Resistance

The goal of this prospective follow-up study nested within an open-label randomized controlled trial is to investigate the unexpectedly high prevalence of Ascaris lumbricoides infection observed 3-4 months after school-based mass drug administration with ivermectin plus albendazole (IVM-ALB) or albendazole alone (ALB) in Kisoro District, South-Western Uganda. By assessing initial treatment response and subsequent infection dynamics, the study will help clarify whether reduced drug efficacy, suboptimal treatment coverage, reinfection, or a combination of these factors may explain the previous findings.

The main questions the study aims to answer are:

  • How effective are IVM-ALB and ALB against A. lumbricoides at 3 weeks, based on egg reduction and cure rates?
  • How often do A. lumbricoides and other soil-transmitted helminth infections recur by 3 months?
  • How effective are the treatments against Trichuris trichiura and hookworm?
  • What can genetic characterization of Ascaris eggs reveal about parasite populations and potential drug resistance markers?

The study will enrol 450 pupils aged 5-14 years from three primary schools, which participated in the previous mass drug administration evaluation. In each school, 150 pupils will be randomly assigned equally to receive a single oral dose of:

  • ivermectin (200 µg/kg) plus albendazole (400 mg); or
  • albendazole (400 mg) alone.

Each treatment arm will include 225 pupils overall. Children will be included regardless of baseline infection status, following parental/guardian informed consent and child assent. Other pupils will receive routine albendazole under national deworming guidelines.

Stool samples will be collected before treatment and at 3 weeks and 3 months. Duplicate Kato-Katz thick smears will quantify A. lumbricoides, T. trichiura and hookworm eggs. The primary outcome is the arithmetic mean egg reduction rate for A. lumbricoides at 3 weeks. Secondary outcomes include cure rates at 3 weeks, reinfection rates at 3 months, egg reduction and cure rates for T. trichiura and hookworm, and genetic characterization of Ascaris populations and potential resistance markers. Adverse events will be recorded through passive safety monitoring.

研究概览

研究类型

介入性

注册 (估计的)

450

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Kampala、乌干达
        • Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

5年 至 14年 (孩子)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Informed consent provided by parent/guardian and assent provided by pupil
  • School-aged children (5-14 years) enrolled in the respective study schools
  • Able and willing to provide a stool sample before and 3 weeks and 3 months post-treatment

Exclusion Criteria:

  • Presence or signs of major systemic illness
  • Recent use of anthelmintic drugs in the 4 weeks before treatment
  • Known allergy to study medication (i.e. benzimidazoles or ivermectin)
  • Participation in other clinical trials

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:IVM (200 µg/kg) + ALB (400 mg)

A single tablet of albendazole (400mg) plus 200 µg/kg of ivermectin, provided as single oral dose.

Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO

其他名称:
  • 曾泰尔

World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.

其他名称:
  • 舒美醇
  • 麦基赞
有源比较器:ALB (400mg)

A single tablet of albendazole (400mg), provided as single oral dose.

Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO

其他名称:
  • 曾泰尔

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Egg Reduction Rates (ERRs) for A. lumbricoides infection at 3 weeks post-treatment
大体时间:3 weeks after treatment

Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the duplicate Kato-Katz thick smears and multiplying this number by a factor of twelve. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment. Egg reduction for A. lumbricoides infection will then be calculated as change in egg counts from baseline to 3 weeks post-treatment.

3 weeks after treatment

次要结果测量

结果测量
措施说明
大体时间
Number of participants A. lumbricoides egg negative at 3 weeks post-treatment (cured)
大体时间:3 weeks after treatment

The conversion from being egg positive pre-treatment to egg negative post-treatment, or cure rate (CR).

3 weeks after treatment
Number of participants egg negative at 3 weeks with soil-transmitted helminth infections 3 months post-treatment (reinfected)
大体时间:3 months after treatment

Number of participants that converted from egg negative with Ascaris lumbricoides, Trichuris trichiura and/or hookworm infections at 3 weeks post-treatment to egg positive after 3 months.

3 months after treatment
Number of participants with concomitant soil-transmitted helminth infections egg negative at 3 weeks post-treatment (cured)
大体时间:3 weeks after treatment

Number of participants that converted from egg positive with Trichuris trichiura and/or hookworm infections to egg negative after 3 weeks.

3 weeks after treatment
Egg-reduction Rates (ERRs) against concomitant soil-transmitted helminth infections
大体时间:3 weeks after treatment

Percent change in arithmetic and geometric mean eggs per gram of stool from before to after treatment. ERRs will be calculated for Trichuris trichiura and hookworm infections as described in outcome 1.

3 weeks after treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jennifer Keiser, Prof.、Swiss Tropical & Public Health Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年2月1日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2026年10月7日

首先提交符合 QC 标准的

2026年10月7日

首次发布 (实际的)

2026年10月14日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

There is a data sharing agreement between Swiss TPH and Uganda MoH in place. Data may be shared with other researchers upon request.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅